Agenus Inc. has announced a strategic collaboration with Zydus Lifesciences, valued at $141 million, to advance the development of BOT/BAL and expand Zydus' biologics manufacturing capabilities in the United States. The agreement includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities in Emeryville and Berkeley, California. Agenus is set to receive up to an additional $50 million in contingent payments based on production orders. As part of the deal, Agenus will become Zydus' first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL, aimed at ensuring BLA and launch readiness. Additionally, Zydus will gain an exclusive license for BOT/BAL in India and Sri Lanka, along with a $16 million equity investment in Agenus. This collaboration reflects a strengthened partnership between the U.S. and India in biopharma and aims to secure strategic capital for global regulatory engagement and commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.